Spruce Street Capital LP Buys New Shares in Kiniksa Pharmaceuticals International, plc $KNSA

Spruce Street Capital LP bought a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the 4th quarter, HoldingsChannel.com reports. The fund bought 434,982 shares of the company’s stock, valued at approximately $17,943,000. Kiniksa Pharmaceuticals International accounts for about 5.9% of Spruce Street Capital LP’s holdings, making the stock its 6th biggest position.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Mark Sheptoff Financial Planning LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 1.6% during the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock valued at $674,000 after purchasing an additional 250 shares during the last quarter. Mariner LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 2.0% during the 4th quarter. Mariner LLC now owns 13,519 shares of the company’s stock valued at $558,000 after purchasing an additional 266 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. CWM LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 3.9% during the 4th quarter. CWM LLC now owns 20,605 shares of the company’s stock valued at $850,000 after purchasing an additional 764 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 4.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock valued at $701,000 after purchasing an additional 771 shares during the last quarter. Institutional investors own 53.95% of the company’s stock.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, COO Ross Moat sold 1,703 shares of the firm’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $46.69, for a total value of $79,513.07. Following the completion of the sale, the chief operating officer directly owned 12,029 shares of the company’s stock, valued at approximately $561,634.01. This trade represents a 12.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the sale, the director directly owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. This represents a 51.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals International Stock Up 0.9%

Shares of KNSA opened at $52.34 on Tuesday. The firm has a fifty day simple moving average of $50.57 and a two-hundred day simple moving average of $46.03. Kiniksa Pharmaceuticals International, plc has a twelve month low of $26.27 and a twelve month high of $59.87. The stock has a market capitalization of $4.03 billion, a P/E ratio of 58.16 and a beta of 0.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The firm had revenue of $214.27 million during the quarter, compared to analysts’ expectations of $206.11 million. During the same period last year, the company posted $0.11 EPS. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. Sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on KNSA. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, June 8th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Monday, May 4th. Canaccord Genuity Group increased their price target on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Finally, Wells Fargo & Company increased their price target on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $60.86.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.